Last Update 01 May 26

Fair value Increased 2.56%

LFCR: CDMO Site Transfers And 2028 Commercial Ramps Will Drive Upside

Narrative update on Lifecore Biomedical

The updated analyst price target for Lifecore Biomedical moves to $6.67 from $6.50. Analysts point to slightly higher modeled fair value, a modestly adjusted discount rate, incremental changes to revenue growth and margin assumptions, and a higher future P/E multiple following recent target revisions and rating changes.

Analyst Commentary

Recent price target changes and rating updates on Lifecore Biomedical highlight a split between analysts who are leaning more positive on long term potential and those who are focused on nearer term execution risk and guidance.

Bullish Takeaways

Bullish analysts have raised price targets modestly, reflecting updated models that incorporate slightly higher fair value assumptions and a higher future P/E multiple.
The upgrade to an Outperform rating aligns with a view that Lifecore can create additional long term value through new programs, including site transfer wins that could expand the revenue base over time.
Some see the updated timeline for a potential "breakout year" as a shift in timing rather than a change in long term opportunity, which supports maintaining constructive views on the business trajectory.
Positive commentary around the most recent quarter being "solid" indicates that, operationally, the company is viewed as executing reasonably well even if the market reaction to guidance has been cautious.

Bearish Takeaways

Bearish analysts have lowered price targets by a meaningful amount, indicating reduced conviction in near term upside relative to prior expectations.
The Equal Weight rating signals a more balanced stance, where current valuation is seen as more fully reflecting both the opportunities and the risks.
FY26 guidance came in below prior expectations, and the timing of commercial ramps has been pushed outward, which adds uncertainty around the pace of revenue growth and margin progression.
Even those who are constructive on the long term opportunity acknowledge that the revised outlook may delay when investors might see the company reach its targeted scale and profitability, which can weigh on sentiment and target setting today.

What's in the News

Lifecore signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer, including a commercial site transfer for a currently marketed product and an expansion to manufacture a second delivery system for an ophthalmic treatment product. Both programs are expected to be additive to the high value late stage pipeline and to contribute to 2028 commercial revenue (Key Developments).
The company entered a CDMO manufacturing services agreement with a new aesthetics customer for an established, market approved product, covering technical transfer and sterile manufacturing for products sold in the U.S. The agreement includes the potential for commercial revenue within 24 months and references a targeted 2029 revenue CAGR of 12%, described as the third commercial site transfer signed since October 2025 (Key Developments).
Lifecore provided earnings guidance for 2026, 2027 and 2028, with 2026 revenue expected to be approximately $120,000 to $125,000 and a net loss of $33,400 to $28,900. The company commented on customer related factors, referenced modest revenue growth for 2027 and noted expectations for significant revenue growth in 2028 driven by existing customer program expansion, increasing contributions from development programs, commercialization of the late stage pipeline and a more diversified customer base (Key Developments).
Lifecore and Indomo entered a new development services agreement for corticosteroid drug candidate DT-001 combined with the ClearPen intradermal self injection device for inflammatory acne lesions. Lifecore is to supply engineering and clinical batches to support planned studies ahead of an anticipated Phase 2 trial start in 2026, following an earlier agreement for formulation and process optimization (Key Developments).

Valuation Changes

Fair Value: Updated modeled fair value moves from $6.50 to $6.67, representing a small upward adjustment in the target level.
Discount Rate: The discount rate shifts slightly from 9.50% to about 9.53%, a modest change in the rate used to value future cash flows.
Revenue Growth: The long run revenue growth assumption edges from about 7.09% to about 7.10%, a very small adjustment.
Net Profit Margin: The net profit margin assumption moves from about 15.32% to about 15.41%, reflecting a slight change in expected profitability.
Future P/E: The future P/E multiple increases from roughly 13.0x to about 13.2x, indicating a marginally higher valuation multiple in analyst models.

0 views

Key Takeaways

Expanding partnerships, operational enhancements, and regulatory credibility are driving Lifecore's momentum in biopharma manufacturing, supporting stronger contract wins and profitability.
Rising demand for injectable and HA-based drugs, along with new market entries, is broadening Lifecore's addressable market and cementing a foundation for sustained growth.
Heavy reliance on key customers, margin compression, and sector risks challenge profitability and growth, while macroeconomic pressures threaten long-term financial stability and flexibility.

Catalysts

About Lifecore Biomedical

Operates as an integrated contract development and manufacturing organization in the United States.What are the underlying business or industry changes driving this perspective?

The company is benefiting from increased development agreements and partnerships with both new and existing customers, including high-value programs in late-stage development (such as the GLP-1 and ophthalmic programs), positioning Lifecore to capitalize on growing biopharma R&D spending-this should support future top-line growth and provide greater revenue visibility as pipeline products reach commercialization.
Growing demand for injectable and HA-based pharmaceuticals, driven by aging demographics and a rise in chronic illnesses like osteoarthritis and ophthalmic disorders, is expanding Lifecore's target market; recent volume increases and take-or-pay commitments from major customers, including upcoming expansions into new regions (notably Asia Pacific), suggest a foundation for sustained revenue and earnings growth.
Lifecore has executed significant operational improvements-rightsizing the workforce, implementing manufacturing automation, and introducing an enterprise resource planning (ERP) system-all of which are likely to increase operating leverage, improve margins, and reduce SG&A as a percent of revenue, thus contributing to higher future profitability.
The shift toward pharmaceutical manufacturing onshoring and greater regulatory focus on supply chain security is driving increased outsourcing to specialized CDMOs in the US like Lifecore-management commentary and customer pipeline activity indicate that these industry dynamics can support continued contract wins, boosting long-term volume growth and recurring revenues.
The company's strong quality management systems, recent positive FDA audit, and investment in business development talent have upgraded capabilities and customer perception, enhancing Lifecore's ability to win new contracts and sustain its reputation; this operational credibility is expected to translate into a higher win rate for projects and improved long-term revenue growth.

Lifecore Biomedical Earnings and Revenue Growth

Lifecore Biomedical Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Lifecore Biomedical's revenue will grow by 7.1% annually over the next 3 years.
Analysts are not forecasting that Lifecore Biomedical will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Lifecore Biomedical's profit margin will increase from -26.7% to the average US Life Sciences industry of 15.4% in 3 years.
If Lifecore Biomedical's profit margin were to converge on the industry average, you could expect earnings to reach $24.5 million (and earnings per share of $0.65) by about May 2029, up from -$34.5 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.5x on those 2029 earnings, up from -5.5x today. This future PE is lower than the current PE for the US Life Sciences industry at 31.4x.
Analysts expect the number of shares outstanding to grow by 0.19% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.53%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Lifecore remains highly dependent on a small number of large customers, with growth in HA manufacturing and revenue heavily concentrated in a single partner's supply chain shift; this customer concentration exposes the company to sudden revenue declines and earnings volatility if relationships change, contracts are lost, or terms are renegotiated, directly impacting future revenue visibility and profit stability.
The company's recent financials reflect a net loss of $38.7 million for FY2025 versus net income the prior year, with declining gross profits in CDMO business segments and only marginal total revenue growth (0.5% YoY); these trends suggest persistent challenges in scaling profitability and improving net margins, raising questions about Lifecore's ability to deliver sustained earnings growth.
Industry-wide margin compression and pricing pressure are foreseeable as competition intensifies in the injectable and hyaluronic acid contract manufacturing market; Lifecore's midterm margin expansion targets could be undermined if competitive or regulatory forces drive down pricing or increase cost of compliance, negatively affecting EBITDA and net margins.
Advances in alternative drug delivery technologies or synthetic/biosynthetic substitutes for hyaluronic acid could erode demand for Lifecore's core offerings; such secular shifts in the biotechnology sector would hurt long-term top-line growth and threaten the relevance of the current product portfolio, putting revenues at risk.
Lifecore's recently strengthened balance sheet is partly due to noncore asset sales, but the company remains exposed to broader macro risks such as rising interest rates, capital market volatility, and elevated compliance costs; these factors can increase operational overhead, borrowing costs, and refinancing risk, further squeezing net income and limiting the financial flexibility needed for long-term expansion.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $6.67 for Lifecore Biomedical based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $5.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $159.0 million, earnings will come to $24.5 million, and it would be trading on a PE ratio of 13.5x, assuming you use a discount rate of 9.5%.
Given the current share price of $5.07, the analyst price target of $6.67 is 24.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Lifecore Biomedical?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Biopharma Partnerships And Injectable Demand Will Expand Global Reach